Rituparna Das | Therapeutic Area Head, Respiratory Vaccines
Moderna

Rituparna Das, M.D., Ph.D., is Senior Vice President and Therapeutic Area Head for Infectious Diseases, Rare Diseases and Therapeutics at Moderna, where she leads clinical development across a broad portfolio of mRNA medicines. A physician-scientist and global development leader, Dr. Das has led the development and regulatory approval of multiple vaccines, including Spikevax, mRESVIA, and most recently mFLUSIVIA, bringing a new influenza vaccine into Moderna’s respiratory portfolio. Prior to Moderna, she held leadership roles at Merck developing vaccines for Ebola, CMV, HPV, and rotavirus. She is board-certified in internal medicine, infectious diseases, and pediatrics and holds an M.D. from Jefferson Medical College and a Ph.D. in Immunology from Yale University.

Appearances:

Day 1 (20th October) @ 10:15

One Shot, Many Frontiers: Combination Vaccines for a Healthier Lifetime

How can combination vaccines support life-course immunisation strategies and close immunity gaps at every age?
Could combining priority pathogens in a single shot improve vaccine coverage, or will it introduce new barriers for uptake and delivery?
What is the economic value of combination vaccines?
What standards do we need to ensure multi-antigen vaccines perform consistently without compromising safety or effectiveness?
What strategies can we use to ensure broad accessibility of combination vaccines, including considerations around technology, adjuvants, and formulation?
Which pairings have the strongest potential to reduce global disease burden, especially in regions with limited resources?

Melanie Saville, Chief Scientific Officer, PATH